miR-590 - A Novel Candidate microRNA in Acute Myeloid Leukemia

Pradeep SathyanarayanaAccording to Surveillance Epidemiology and End Results (SEER) cancer statistics review, it is estimated that 13,780 men and women will be diagnosed with and 10,200 will die of acute myeloid leukemia (AML) in 2012 from this disease. Acute myeloid leukemia (AML) poses difficult challenges both to cancer researchers and cancer therapists. It is not a single disease but a group of highly variable subtypes that tend to have different presenting features and different responses to treatment.

Recent evidence suggests that AML originates in early blood-forming cells termed “leukemia stem cells.” Thus, identification and targeting of cancer stem cells has become a high priority for research. Our proposal seeks to address this problem by focusing on microRNAs (miRNAs). MicroRNAs are emerging as important factors in cancer pathophysiology, including the leukemias. It is our position that a comprehensive understanding of the role of microRNA in leukemia is needed to fully exploit the therapeutic potential of these small intriguing molecules. In this proposal, I will investigate a microRNA that we recently discovered to be highly elevated in the bone marrow cells of AML patients. We propose to concentrate on this single miRNA, called miR-590, because of its apparent dominant position at the top of the miRNA hierarchy in AML cells. Investigations include use of “humanized mouse models”, which allows recapitulation of human leukemia in mice and facilitates the understanding of miR-590’s role in promoting AML.

Successful completion of the proposed experiments will provide critical new insights into the impact of this microRNA on both the pathogenesis and targeted treatment of AML. Ultimately, it may be possible to target leukemia stem cells using miRNA-based therapeutics that build on data generated by the proposed research. We are confident that by fully characterizing the role of miR-590 in normal and leukemic blood cells, it will be possible to accelerate the development of improved therapy for this devastating cancer.

Watch an interview with Dr. Sathyanarayana and WMTW Channel 8's Steve Minich:

 

Organization: 
Maine Medical Center Research Institute
Researcher: 
Pradeep Sathyanarayana, PhD
Grant Amount Given: 
$168,906
Year Issued: 
2013
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Leukemia
Grant Duration: 
2 Year Accelerator Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2015 Integrating Personalized Risk Information in Low-Dose CT (LDCT) Screening for Lung Cancer $100,000 Research Maine Medical Center Research Institute
2015 Creating a Centralized Biospecimen Resource for Cancer Research $199,830 Research Maine Medical Center Research Institute
2015 Tumor Registry Electronic Medical Record Linked Data Resource: TREMR $191,230 Research Maine Medical Center Research Institute
2014 FOXD1: The Key to Kidney Tumors? $178,409 Research Maine Medical Center Research Institute
2013 The Role Of Spry1 And Spry4 In Triple-Negative Breast Cancer Differentiation And Cancer Stem Cell Self-Renewal $156,315 Research Maine Medical Center Research Institute
2013 Development of a Novel Small Molecule Inhibitor for Breast Cancer Treatment $169,861 Research Maine Medical Center Research Institute
2013 miR-590 - A Novel Candidate microRNA in Acute Myeloid Leukemia $168,906 Research Maine Medical Center Research Institute
2013 Notch Signaling In A Mouse Model Of Acute Promyelocytic Leukemia $50,000 Research Maine Medical Center Research Institute
2013 Numb5 & Numb6 promote Invasive Behavior of Breast Cancer by Inducing Epithelial-Mesenchymal Transition $49,989 Research Maine Medical Center Research Institute
2011 Passport to Care $10,000 Navigator Maine Medical Center Research Institute
2010 Targeting Stromal Cell Interactions to Reduce Prostate Cancer $81,175 Research Maine Medical Center Research Institute
2010 Regulation of Hematopoietic Stem Cells by Heparin Binding Domain of IGFBP-2 $82,535 Research Maine Medical Center Research Institute
2010 Role of Cryptic Activation Site within B1 Integrins in Breast Tumor Growth $91,919 Research Maine Medical Center Research Institute
2009 Functional Tests of PODXL's Contributions to Tumorigenesis $80,000 Research Maine Medical Center Research Institute
2008 Genetic Model of TGFB Receptor-Dependent Supression of Prostate Cancer Metastasis $78,413 Research Maine Medical Center Research Institute
2008 FGF-Mediated Tumor Growth Induced by Noth Signaling Inhibition $86,191 Research Maine Medical Center Research Institute
2007 Twist dimers as markers of tumor metastasis $73,000 Research Maine Medical Center Research Institute
2007 Sprouty 4: a possible repressor of Id protein function in breast cancer $72,000 Research Maine Medical Center Research Institute